https://pbs.twimg.com/media/FhNSDSaWIAQ2YQo.png
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz

Links:

Comparative Evaluation of Adverse Events Associated with Subcutaneous Inflixima… https://acrabstracts.org/abstract/comparative-evaluation-of-adverse-events-asso…
Richard Conway
RichardPAConway
14-11-2022
×